European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials

•Outcome measures in trials for ambulant DMD patients are the 6 MWT, NSAA and 4SC.•Limitations related to patient motivation during the assessment for these measures.•The wearable device measurement intends to overcome such limitations.•SV95C measured is an acceptable secondary endpoint in pivotal or exploratory trials Development of novel therapies for Duchenne muscular dystrophy (DMD) are driving the need for more efficient ways of detecting changes in disease- progression in DMD [1]. However, medicines’ approval must be based on outcome measures that are acceptable from a regulatory perspective. In this article, European regulators provide an update on the recent regulatory consideration of a new endpoint (Stride Velocity 95th Centile (SV95C)) that could be used in therapeutic DMD trials. This new endpoint aims to quantify a patient's ambulation directly, reliably and continuously in a home environment with a wearable device.